The Health Council of the Netherlands has delivered a clear verdict: gender-affirming care for trans young people is lawful, effective, and beneficial. The review found zero cases of regret among Dutch patients, warned that withholding care is not a neutral choice, and called reducing waiting times a moral imperative. This is the latest in a series of European countries reaffirming the care.

What the review actually said

Erin Reed has reported on the Health Council of the Netherlands' conclusions, and I am grateful for the detail she brought to this. The council is the country's highest scientific advisory body. This was not a quick survey or a political statement; it was a two-year systematic review, chaired by a professor of research methodology, with seats at the table for professors of health law and medical ethics alongside practising physicians and psychiatrists. They ran literature searches, consulted outside experts, and yes, they invited Hilary Cass herself. They looked at her review and concluded it was not applicable to Dutch care.

Their conclusions were unambiguous. The care achieves its intended physical effects. Mental health outcomes improve. The rate of people stopping treatment is between zero and three and a half per cent among those who began as minors, and no cases of regret were found in the studies. Where young people did stop puberty blockers, the most common reason was that their gender dysphoria had resolved, which is, as the council noted, exactly what blockers are designed to allow for: time to explore, without irreversible changes forcing a decision.

Delay is not a safe choice

The passage I keep coming back to is this one: "Non-treatment is therefore not a neutral option. In the public debate, treating is often presented as intervening, while waiting is treated as self-evident."

I have been saying this for years. Many people have. But there is something about seeing it written into an official advisory document, by a body of this standing, in terms this precise, that still moves me. The council spelled out what delay actually costs: unwanted and often irreversible physical changes, deteriorating mental health, and some young people turning to unregulated hormones because careful care is not available to them. It called reducing waiting times "morally urgent." That is not cautious language. That is a body that has looked honestly at what withholding care does to children and named it for what it is.

The mental health data in the review tell the same story. Trans young people report worse mental health than their cisgender peers before treatment begins. After starting puberty blockers, they report better mental health: fewer emotional problems, fewer depressive symptoms, lower rates of suicidality and self-harm. The council also pointed out what untreated dysphoria takes from a young person's life, fewer chances to form an identity, develop talents, and make plans for the future. They called it a damage to "the right to an open future." That framing is exactly right.

The evidence question, answered properly

One of the most persistent arguments used against trans youth care is that the evidence is too weak, that without large randomised controlled trials we cannot act. The Dutch council addressed this directly. Randomised controlled trials are largely off the table in paediatric medicine, because children and families refuse to join no-treatment control groups, and because treatment visibly changes the body, making blinding impossible. The same is true across much of children's medicine. A low GRADE rating in this context does not mean the evidence is insufficient; it means the evidence is as good as paediatric evidence tends to be, and that properly practised evidence-based medicine weighs it alongside clinical expertise and the patient's own goals. The council said so plainly. The argument that this care is uniquely unsupported by evidence has now been examined by one of Europe's most rigorous scientific bodies and found to be false.

Europe is not pulling back

For years, a particular story has circulated: that Europe is retreating from trans youth healthcare, that restrictions in the United Kingdom represent a continental trend, that the world is catching up with gender-critical concerns. That story was never true, and the Dutch review makes it harder than ever to sustain. Germany, Austria, and Switzerland issued joint guidelines recommending the care. France's paediatric endocrinologists published their first national consensus endorsing it. And now the Netherlands, the country that pioneered this care, has reviewed it thoroughly and concluded once again that it gives trans young people their greatest chance to thrive.

The UK is not Europe. What happened here, driven in significant part by a review the Dutch council declined to apply to their own context, is not a reflection of what the evidence says. It is a reflection of a political moment. The Dutch review is a reminder that the political moment and the science are not the same thing.

What I hope people take from this

There will be trans young people reading about this review, or whose parents are reading about it, who are currently on a waiting list measured in years. There will be families who have been told that delay is the cautious choice, the safe path, the responsible thing. I want them to know that the highest scientific advisory body in the country that pioneered this care has looked carefully at the evidence and said that delay causes harm, that the care works, that regret is rare, and that access to treatment quickly is a matter of the right to health.

That is not ideology. That is a two-year systematic review conducted by a body that invited its critics to participate and still arrived at these conclusions. I hope people start listening.

If there is a news story you would like me to cover then just let Sammy know.

Dr Helen Webberley is a Gender Specialist, Medical Educator, and advocate, and the founder of GenderGP. She writes about gender identity, trans healthcare, and the lives at the centre of both.